“Assessing the Benefits of Rosiglitazone in Women With Polycystic Ovary Syndrome through Its Effects on Insulin-Like Growth Factor 1, Insulin-Like Growth Factor-Binding Protein-3 and Insulin Resistance: A Pilot Study”. 2012. Clinics 67 (3): 283-87. https://doi.org/10.6061/clinics/2012(03)14.